Active Biotech regained the global development and commercialization rights to the neurodegenerative disease drug laquinimod from Teva Pharmaceutical Industries.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2018-09-05 12:29:142018-09-10 01:27:08Teva Returns Laquinimod Rights to Active Biotech
